Regeneron is building a $2 billion production facility in Saratoga Springs that will allow the Tarrytown drugmaker to double ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

New details have emerged about what Regeneron is planning for the Saratoga Springs site it acquired last year.

Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending shares up ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

A large group of seniors at Ardsley High School has entered the 2025 Regeneron Science Talent Search, the nation’s oldest and ...

Federal enforcement of the False Claims Act (FCA) against healthcare and pharmaceutical companies—especially based on alleged ...